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Abstract: Antineoplastic drugs are hazardous chemical agents used mostly in the treatment of 
patients with cancer, however health professionals that handle and administer these drugs can 
become exposed and develop DNA damage. Comet assay is a standard method for assessing DNA 
damage in human biomonitoring and, combined with formamidopyrimidine DNA glycosylase (FPG) 
enzyme, it specifically detects DNA oxidative damage. 
The aim of this study was to investigate genotoxic effects in workers occupationally exposed to 
cytostatics (n = 46), as compared to a control group with no exposure (n = 46) at two Portuguese 
hospitals, by means of the alkaline comet assay. The potential of the OGG1 Ser326Cys 
polymorphism as a susceptibility biomarker was also investigated. Exposure was evaluated by 
investigating the contamination of surfaces and genotoxic assessment was done by alkaline comet 
assay in peripheral blood lymphocytes. OGG1 Ser326Cys (rs1052133) polymorphism was studied by 
Real Time PCR. 
As for exposure assessment, there were 121 (37%) positive samples out of a total of 327 
samples analysed from both hospitals. No statistically significant differences (Mann-Whitney test, 
p > 0.05) were found between subjects with and without exposure, regarding DNA damage and 
oxidative DNA damage, nevertheless the exposed group exhibited higher values. Moreover, there 
205 
AIMS Genetics  Volume 2, Issue 3, 204–218. 
was no consistent trend regarding the variation of both biomarkers as assessed by comet assay with 
OGG1 polymorphism.  
Our study was not statistically significant regarding occupational exposure to antineoplastic 
drugs and genetic damage assessed by comet assay. However, health professionals should be 
monitored for risk behaviour, in order to ensure that safety measures are applied and protection 
devices are used correctly. 
Keywords: DNA damage; Comet assay; OGG1 polymorphism; antineoplastic drugs; occupational 
exposure; biomonitoring 
 
1. Introduction  
Exposure of patients and health professionals to mixtures of antineoplastic drugs in hospital 
settings leads to unpredictable and unique effects. This is due to differences in practice at hospital 
oncology departments, namely regarding the number of patients, the availability of protection 
devices, and safety procedures employed by the clinical staff. Health care workers who prepare or 
administer hazardous drugs or work in areas where such drugs are used may be exposed to these 
agents by direct contact with contaminated workplace surfaces, clothing, medical equipment, patient 
excreta, and other contaminated materials [1–3]. 
Exposure may occur by inhalation, resulting from aerosolization of powder or liquid during 
reconstitution, and by spillage taking place while preparing or administering to patients. It is well 
known that exposures to even very small concentrations of certain drugs may be hazardous for 
workers who handle or work near them [1,4,5].  
Cytostatic drugs have been proven to be mutagens, carcinogens and teratogens [6–11]. The first 
chemotherapeutics developed were chemicals that interact directly with DNA by covalent binding or 
other, or indirectly by interfering with DNA synthesis. Compounds that inhibit the mitotic spindle 
formation and those that affect endocrine function are also used in cancer chemotherapy [12]. These 
drugs are often used in combination to achieve synergistic effects on tumour cells resulting from 
their different modes of action. However, most if not all of such chemical agents are generally 
nonselective and, along with tumour cells, normal cells may also undergo cytotoxic/genotoxic 
damage [5,13,14]. According to European Guidelines (Corrigendum to Directive 2004/37/EG), any 
use of carcinogenic, mutagenic or teratogenic substances, including their application in health care 
settings, are deemed to be of the highest risk level [8–11,15].  
Comet assay has become one of the standard methods for assessing DNA damage, with a wide 
range of applications, namely in genotoxicity testing, human biomonitoring and molecular 
epidemiology, as well as in fundamental research on DNA damage and repair [16–20]. To make the 
assay more specific as well as more sensitive, an extra step is added to the assay using 
formamidopyrimidine DNA glycosylase (FPG) enzyme that detects the major purine oxidation 
product 8-oxoguanine (8-OHdG) [16,21–23] providing information about DNA oxidative damage. 
The cellular defense system against 8-OHdG mutagenesis involves base excision repair (BER), 
nucleotide excision repair (NER), and mismatch repair. However, BER via DNA glycosylase (OGG1) 
represents the main protection mechanism of the integrity of human DNA with respect to 
8-OHdG [24]. OGG1 is considered to be the main enzyme responsible for the removal of 8-OHdG in 
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humans, removing it when it is paired with cytosine [25,26] and the inactivation of OGG1 appears to 
play a role in the multistage process of carcinogenesis. The human OGG1 gene is located on 
chromosome 3 (3p26), and encodes a bifunctional DNA glycosylase endowed with an AP lyase 
activity. This is a region frequently lost in various types of cancer, especially in small-cell lung 
cancers where loss of heterozygosity in nearly 100% of the cases can be observed [27].  
Loss of the gene would abrogate OGG1 activity imposing an increased risk of mutagenicity on 
the cell due to accumulation of 8-OHdG in DNA [27]. A common polymorphism of this gene, 
Ser326Cys (rs1052133) a C→G polymorphism in codon 326 at exon 7 [28] is associated with an 
increased risk of cancer [29]. This polymorphism is present in 33–41% of the Caucasian population [30]. 
The aim of this study is to evaluate genotoxic effects in workers occupationally exposed to 
cytostatics at two Portuguese hospitals by means of the alkaline comet assay and investigate the 
potential of the OGG1 Ser326Cys polymorphism as a susceptibility biomarker. 
2. Materials and Method 
2.1. Subjects of study 
The study is based upon a sample of 46 occupationally exposed workers—pharmacists, 
pharmacy technicians and nurses and a sample of 46 non-exposed control subjects. The exposed 
group was formed by workers from two hospitals at the Lisbon region, and the control group 
included workers from an academic institution, namely teachers and office workers, chosen for 
having no contact with cytostatic drugs and for being statistically comparable to the exposed group, 
in terms of sex ratio and age distribution.  
This study was performed abiding by high ethical standards and received the necessary 
approvals. All the participants were informed about the aim and experimental details of the study and 
gave their informed consent. Each participant completed a standardized questionnaire that covered a 
detailed medical, family and dietary history, including variables known to influence cytogenetic 
endpoints (exposure to potential mutagens, oncological therapeutics, and lifestyle activities). The use 
of individual and collective protection equipment was also assessed by the questionnaire. 
2.2. Exposure assessment 
Cyclophosphamide (CP), 5-Fluorouracil (5FU) and Paclitaxel (PTX) were used as surrogate 
markers for surfaces contamination by cytotoxic drugs, since those drugs are among the most used 
on a daily basis in both hospitals, both in frequency and amount. A similar approach has been used in 
previous studies [31–35].  
Surface areas of 100 cm
2
, defined by a stainless frame with an internal size of 10 × 10 cm were 
wipe sampled with gauze moistened with ethyl-acetate as described in Schmaus et al. [36]. For 
irregular surfaces such as phones, armrests and handles the wiped area was estimated and the result 
was used to calculate contamination. 
Extraction was performed as described in Schmaus et al. [36]. Briefly, the wipes were extracted 
with 15 mL of acetonitrile:methanol:water (10:25:65) for 20 minutes at room temperature in a bottle 
roller homogenizer. Extracts were filtered through a 0.22 µm filter prior to injection. Separation and 
quantification was performed according to Larson et al. [31] on a Thermo-UNICAM Surveyor 
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HPLC-DAD; 100 µL sample loop; column Hypersil-GOLD 15 × 5 × 4.6 with a guard column; 
mobile phase of acetonitrille:methanol:water (19:13:68) at a flow of 0.8 mL min
−1
. All HPLC grade 
solvents were purchased from VWR International. CP, 5FU and PTX were purchased from Sigma®. 
For all the drugs, calibration curves were performed after extraction of spiked wipes. Each sample 
was injected in triplicate. 
2.3. Genotoxicity assessment  
Heparinized blood samples were obtained by venipuncture from each subject between 10 a.m. 
and 12 p.m. and the isolated lymphocytes were cryopreserved following the protocols of Singh and 
Lai [37] and Duthie et al. [38]. Assessment of genotoxic effects was conducted by applying the 
alkaline comet assay in peripheral blood lymphocytes, as described in Collins and Azqueta [39]. The 
FPG [kindly donated by Prof. Andrew Collins (Department of Nutrition, University of Oslo, 
Norway)] protocol was performed also according to Collins and Azqueta [39]. The slides dried at 
room temperature, were stained with DAPI (1 µg/mL) and then visualized. All samples were coded 
and analyzed under blind conditions. Slides were scored by one single observer using Zeiss 
AxioScope.A1 fluorescence microscope and Comet Assay IV capture system (Perceptive Instruments) 
and 50 nucleoids were scored per gel, following the parameters described by Collins [40]. 
2.4. Polymorphism analysis 
Whole blood samples were collected and stored at −20 ºC until total white cell’s DNA was 
extracted by blood spot. Briefly, the whole blood was defrosted and 200 µL were dropped in 3 MM 
chromatography paper (Watman
TM
) and air dried. Two samples of each biological sample were taken 
with a perforator and put in a microtube with 500 µL of ultrapure water (Milli-Q®). The perforator 
was disinfected between samples with ethanol 70%. Each microtube was placed in the vortex and 
kept at room temperature for 10 min, being centrifuged in the following day at 16.000 g for 2 min. 
The supernatant was eliminated and 200 µL of Chelex at 6% were added in the microtube and mixed 
in the vortex. The microtubes were put at 56 ºC for 10 min and then, after vortex, went for 10 more 
min at 100 ºC. Finally, the microtubes were centrifuged at 6000 g for 2 min and stored at −20 ºC. All 
the laboratory procedures were made in the same institution. 
The OGG1Ser326Cys (rs1052133) genotypes were determined using the TaqMan SNP 
genotyping assay with Real Time PCR (Applied Biosystems). To perform the genotype analysis of 
OGG1 polymorphism the target fragments were amplified in a 20 µL reaction mixture containing 
10 µL TaqManUniversal PCR Master Mix, 1 µL primers/probe, 5 µL MilliQ water, and 4 µL DNA. 
Real Time PCR, was then conducted as follows: 10 min at 95 ºC, 50 cycles of 15 sec at 92 ºC and 
1 min at 60 ºC at iCycler iQ® Multicolor Real-Time PCR Detection System (BIO-RAD). All doubtful 
samples were reanalyzed. 
2.5. Statistical analysis 
Statistical analysis was performed using SPSS for Windows (version 21.0). Variables were 
compared with the Normal distribution using the Shapiro-Wilk test (p > 0.05). Rejection of the null 
hypothesis of underlying normality led us to proceed with non-parametric procedures to compare 
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groups and check associations. The Mann-Whitney, Fisher exact, and Chi-square tests were used to 
compare groups. The association between each of the genotoxicity biomarkers and OGG1 genotypes 
was evaluated by the Kruskal-Wallis test. The analysis of genotype and allele frequency and the 
Chi-square fit test was made with the GenePop on the web software (http://genepop.curtin.edu.au/). 
3. Results 
Population characteristics such as gender distribution, age, years of exposure and tobacco habits 
for the control and exposed groups are shown in Table 1. 
The exposed group was formed by workers from hospitals A and B (46 = 10 + 36 workers, 
respectively). There were no significant differences between the two groups in what concerns gender 
(Fisher exact test, p > 0.999), age (Mann-Whitney test, p = 0.989), years of exposure (Mann-Whitney 
test, p = 0.789), and tobacco habits (Chi-square test, p = 0.066). The statistics of exposure assessment 
to cystostatic drugs, namely cyclophosphamide, 5-fluorouracil, and paclitaxel are presented in 
Table 2. 
Table 1. Demographics of the study population. 
 Control group Exposed group 
Number of subjects 46 46 
Gender 
Females  
Males  
 
34 (73.9%) 
12 (26.1%) 
 
40 (87.0%) 
6 (13.0%) 
p-value (Chi-square test) 0.115 
Age  
(mean ± standarderror of mean, in years) 
Range 
 
39.26 ± 1.42 
20–61 
 
33.85 ± 1.21 
24–58 
p-value (Mann-Whitney test) 0.004 
Years of exposure 
(median ± standard error of mean, in years) 
(median ± interquartile range, in years) 
Range 
n.a. 
 
6.62 ± 0.94 
5.00 ± 5.00 
0.17–30 
Tobacco habits 
Non-smokers 
Smokers 
 
34 (77.3%) 
10 (22.7%) 
 
42 (91.3%) 
4 (8.7%) 
p-value (Chi-square test) 0.066 
n.a.—non-applicable 
There were 121 (37%) positive samples among a total of 327 analysed samples from both 
hospitals. A sample was considered positive when at least one of the three surrogate markers was 
detected. At hospital A, 21 (31.3%) out of 67 samples were contaminated. At hospital B, 100 (38.5%) 
out of 260 samples were positive. Additionally, in Hospital A, 13 samples (19.4%) presented 
contamination with more than one drug and, in Hospital B, 15 samples (5.8%) showed contamination 
by more than one drug. The global percentages of contaminated samples in the two hospitals (31.3 
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and 38.5%) were not statistically different (Chi-square: 1.158, p = 0.28). As for differences in 
percentages of contamination by drug, they were not different for CP and PTX (respectively, 
Chi-square: 1.84, 0.66; p = 0.17, p = 0.42), but the difference in percentage of samples contaminated 
with 5-FU were significantly higher at Hospital A (Chi-square: 18.97, p < 0.01). The median 
concentrations of CP and PTX were significantly different between hospitals (CP: Mann-Whitney 
test, p = 0.001 based on LOD; PTX: Mann-Whitney test, p = 0.001). 
Table 2. Samples contaminated and total samples per hospital (A and B), median 
and interquartile range (IR) regarding cyclophosphamide (CP), 5-fluorouracil 
(5-FU), paclitaxel (PTX), and respective limits of detection (LOD) and 
quantification (LOQ). 
Hospitals CP 
(µg/cm
2
) 
5-FU 
(ng/cm
2
) 
PTX 
(ng/cm
2
) 
Samples with 
contamination 
A 
 
Median 
IR 
1/67 
(1.5%) 
0.18 
0.12 
17/67  
(25.4%) 
13.44 
2.83 
17/67 
(25.4%) 
12.95 
3.12 
21/67 
(31.3%) 
B 
 
Median 
IR 
14/260 
(5.4%) 
1.00 
1.45 
18/260 
(6.9%) 
14.74 
11.07 
54/260 
(20.7%) 
21.38 
31.45 
100/260 
(38.5%) 
Totals 15/327 
(4.6%) 
35/327 
(10.7%) 
71/327 
(21.7%) 
121/327 
(37%) 
LOD (µg/cm
2
) 0.10 3.30 0.167  
LOQ (µg/cm
2
) 0.30 10.00 0.50 
* Number of contaminated samples is not to be summed across columns, because some 
samples are multi-contaminated. 
There was no statistically significant association between the percentage of contaminated 
samples and years of exposure (Mann-Whitney test, p > 0.05), meaning that more experience does 
not necessarily mean less contamination. 
Results obtained for DNA damage (% DNA in Tail) and oxidative DNA damage (FPG) are 
presented in Figure 1. No statistically significant differences (Mann-Whitney test, p > 0.05) were 
found between subjects with and without exposure, regarding both the mean DNA damage 
(p = 0.136) and oxidative DNA damage (p = 0.229). However higher values were observed in the 
exposed group. 
DNA damage and oxidative DNA damage in the exposed group showed no differences between 
hospitals A and B (Mann-Whitney test, p > 0.05)—Figure 2. 
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Figure 1. Box plots of DNA damage (left) and oxidative DNA damage (right) in the 
two groups. 
 
Figure 2. Box plots of DNA damage and oxidative DNA damage between hospitals A 
and B. 
Age, gender, years of exposure and tobacco habits are possible confounding factors that can 
affect genotoxicity measurement and whose effects can be investigated my multiple regression 
analysis within the exposed and the control groups. Age and tobacco did not account for significant 
results (p < 0.05). As for gender, the regression coefficients in the model of % DNA damage in the 
controls indicates that being a woman increases, on average, 6.4% of the % DNA damage in the 
control group (p = 0.022). Genotypic and allelic frequencies of OGG1 Ser326Cys polymorphism are 
presented in Table 3. The population was in Hardy-Weinberg equilibrium (p > 0.05) and there were 
no significant differences in genotypic and allelic frequencies between the exposed and control 
groups (Chi-square fit test, p > 0.05) (Table 3). 
The descriptive statistics concerning the relationship between genotoxicity biomarkers provided 
by comet assay and the OGG1 genotypes studied are shown in Table 4. 
The results show that the carriers of the Ser/Ser genotype have higher median values of DNA 
damage and oxidative DNA damage, in comparison with the other two studied genotypes. However, 
211 
AIMS Genetics  Volume 2, Issue 3, 204–218. 
the Kruskal-Wallis test did not reject the null hypothesis of equality among OGG1 genotypes 
regarding the means of the two comet assay parameters (p > 0.05). 
Table 3. Frequency of genotypes and alleles of OGG1 Ser326Cys 
polymorphism in the study sample, p-value of Fisher’s exact test. 
Gene Genotypes All (%) Exposed (%) Controls (%) p-value 
OGG1 
Cys/Cys 
Ser/Cys 
Ser/Ser 
9 (9.8) 
32 (34.8) 
51 (55.4) 
7 (15.2) 
14 (30.4) 
25 (54.4) 
2 (4.4) 
18 (39.1) 
26 (56.5) 
0.446 
Cys 
Ser 
50 (27.2) 
134 (72.8) 
31 (30.4) 
79 (69.6) 
22 (23.9) 
70 (76.1) 
0.409 
Table 4. Descriptive statistics of DNA damage and oxidative DNA damage 
in the studied population (median ± interquartile range, and range) by 
OGG1 Ser326Cys genotypes in both groups, p-value of Kruskal-Wallis test. 
  Median Interquartil 
Range 
𝜒𝐾𝑊
2  d.f. p 
 
 
OGG1 
Cys/Cys DNA 
Damage 
12.11 16.595 0.059 2 0.971 
Ser/Cys 13.2 14.987 
Ser/Ser 13.4 16.443 
Cys/Cys Oxidative 
DNA 
Damage 
2.78 8.377 0.031 2 0.985 
Ser/Cys 3.37 5.433 
Ser/Ser 4.75 6.139 
4. Discussion 
Healthcare workers handling antineoplastic drugs usually have available protection equipment 
and abide by safety rules to avoid workplace contamination. However, contamination of the working 
environment is still possible, and the safety measures employed can be insufficient to prevent 
exposure [13,32,36]. In addition, workers may not apply all safety measures required for handling 
such substances or some specific working procedures. The antineoplastic drugs handled by 
pharmacists, pharmacy technicians, and nurses studied in this work can interact with DNA, inducing 
double and single strand breaks, crosslinks, alkylations, and DNA intercalations, which could 
account, at least partially, for the genotoxicity observed, even if not yielding statistically significant 
results. 
Therefore, contamination of various surfaces by antineoplastic drugs in workplaces implies an 
increased risk for health care workers who are dermally exposed [43]. 
Contaminated surface samples were found for all surrogate markers in both hospitals. These 
results are a cause for concern, because health effects associated to exposure to carcinogenic, 
mutagenic, and teratogenic substances usually do not depend on a minimum dose but rather on a 
prolonged exposure [6,8,9,11]. Therefore, there is no safety dose threshold regarding exposure to 
these drugs, instead being more appropriate to apply the ALARA principle: keep 
exposure/contamination levels ―As Low As Reasonably Achievable‖ [41]. Widespread contamination 
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was also observed in other studies [13,32,36], despite the implementation of safety procedures for 
handling antineoplastic drugs. Our results showed that the amount of contaminated surfaces varied in 
both hospitals depending on the drugs considered. This is probably due to daily variability in drugs 
use and how it relates with the days when sampling was conducted or due to different working 
procedures and cleaning methods. These two aspects are probably different between hospitals and 
even between the workers involved on the handling and cleaning within the same hospital. 
Some samples were contaminated with more than one drug, bringing up an important point 
regarding risk assessment: exposure is not occurring to one single drug but rather to combinations of 
different antineoplastic drugs and the health effects of such mixtures are unpredictable [2,6,42]. 
Moreover, it was observed that the use of protection devices was frequent in the preparation areas but 
not in other pharmacy areas and administration services, a concern already brought up before [44]. 
The comet assay identifies injuries resulting from recent exposure (over the previous few weeks) 
which are still reparable, such as single and double-strand DNA breaks, alkali labile lesions 
converted to strand breaks under alkaline conditions, and single-strand breaks associated with 
incomplete excision repair sites [5,18]. In particular, the comet assay combined with an enzyme 
which recognizes and cuts specifically oxidized DNA bases, allows for the evaluation of oxidative 
DNA damage [45]. It is one of the most used methods for biomonitoring genotoxicity in blood 
lymphocytes [46], and has been widely used to evaluate the genotoxic effects of exposure to specific 
antineoplastic drugs in several in vitro and in vivo studies [47–53].  
In what concerns comet assay, our findings suggest that occupational exposure to antineoplastic 
drugs in healthcare workers induces DNA damage, as we have found higher mean DNA damage, 
measured by % DNA in tail and oxidative DNA damage (FPG), in the lymphocytes of exposed 
subjects as compared to controls, although without reaching statistical significance (Figure 1). Our 
results are in line with other studies [11,47–52] which used the alkaline comet assay of peripheral 
blood lymphocytes to monitor subjects exposed to antineoplastic drugs, and also did not find 
significant differences between exposed and controls, or the weak significant trend reported by 
Mader et al. [54] who evaluated DNA damage by measuring comet tail moment, and found no 
significant difference between exposed and control subjects either. A possible explanation for the 
lack of statistical significance may have to do with comet assay predominantly detecting 
single-strand breaks and alkali-labile sites induced by antineoplastic drugs [2]. Since both types of 
DNA damage are continuously and efficiently repaired, the damage level measured results from the 
balance between the DNA damage inflicted and the speed of repair [55]. Generally, the type, level 
and persistence of DNA damage in lymphocytes of exposed populations depends on the kind of 
antineoplastic drugs used as well as on the concentrations of drugs producing the mutagenic 
response [55]. Also, antineoplastic drugs are well-known cross-linking agents, which can increase 
the effective molecular weight of DNA, and thereby are known to reduce the ability of DNA with 
strand breaks to migrate in an electric field. The presence of a cross-linking agent could have hidden 
an increase in DNA migration associated with the induction of DNA strand breaks by other 
genotoxic agents, with a higher effect in terms of DNA tail mobility [4].  
Contrary to these findings, other researchers evaluating DNA damage in healthcare workers 
handling antineoplastic drugs were able to show a statistically significant increase in DNA damage 
on the exposed group as compared to controls, using the comet assay [2,4,51,52,55–61]. 
The comet assay is recommended to monitor populations chronically exposed to genotoxic 
agents combined with the cytokinesis-blocked micronucleus assay [46,58]. Our previous published 
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findings assessing genotoxic effects due to antineoplastic exposure in a nursing group, reported a 
statistical significant increase of micronucleus in the exposed group when compared with 
controls [62]. Such results—positive findings with micronucleus and non-significant results by 
comet assay are similar to those reported by Deng et al. [63] in workers occupationally exposed to 
another cytotoxic drug: methotrexate. 
OGG1 is probably the main enzyme responsible for the removal of 8-OHdG in humans, an 
oxidation product believed to play an important role in carcinogenesis because of its abundance and 
high mutagenicity. Epidemiological studies have previously associated the Ser326Cys in OGG1 
genotypes with the risk of different types of cancer, namely esophageal [64], orolaryngeal [65], lung 
cancer [30], larynx [66], colon cancer [67], and gastric cancer [68]. Our results found that Ser/Ser 
carriers presented higher levels of DNA damage and oxidative DNA damage but the differences were 
not statistically significant (Table 4). These results go against studies of Chen et al. [69] that showed 
OGG1 Ser/Ser to have higher repair activity toward 8-OHdG than the OGG1 Cys/Cys, being 
8-OHdG levels in lymphocyte DNA significantly higher in the last genotype. Also, Aka et al. [70] 
and Pawlowska et al. [66] verified that Cys/Cys and Ser/Cys OGG1 genotypes have less DNA repair 
capacity compared to the Ser/Ser OGG1 genotype. Kohno et al. [28] reported that mean 8-OHdG 
levels were similar in peripheral leukocytes expressing either Ser/Ser or Cys/Cys. 
The small size of our sample may have hampered the finding of an association between 
oxidative damage and this polymorphism. Nevertheless, the effect of Ser326Cys genotypes on DNA 
repair capacity may differ with the type and strength of DNA-damaging exposures and may be 
influenced by the interaction between the OGG1 polymorphism and other genetic 
polymorphisms [71]. Moreover, this polymorphism may be in linkage disequilibrium with other 
functional polymorphisms in cancer-related genes [30]. The polymorphism of the OGG1 gene is 
worth an investigation, as a population with decreased OGG1 enzyme activity would be at risk of 
accumulating 8-OHdG in nuclear DNA due to incomplete repair of oxidatively damaged DNA [72]. 
5. Conclusion 
Alkaline comet assay is widely used to detect genotoxic effects induced in vivo by occupational 
exposure to various mutagens. The relative simplicity and quickness of the method, combined with 
the fact that few cells are required for the analysis, makes it an attractive technique for biomonitoring 
purposes in human populations [55]. Our results confirm that it is likely that those continuously 
handling antineoplastic drugs for occupational reasons are at a greater risk of genotoxic damage, 
since the results pointed out a slight increase, however not statistically significant, of genetic damage 
assessed by comet assay. The achieved results can reinforce the importance of keeping and 
continuously improving safety measures to avoid exposure, and the monitoring of these professionals 
for risk behaviour, in order to make sure that such hazardous compounds are properly handled. Since 
genotoxicity may be due to combined effects of all or some of the antineoplastic drugs, it is not 
possible to attribute damage to any particular agent [56]. We have not found an association between 
OGG1 Ser326Cys genotypes and DNA oxidative damage, either because of insufficient sample size 
or because the effect is modulated by other variables. Nevertheless we suggest that the investigation 
of this polymorphism is worth pursuing, given its known epidemiological association with cancer. 
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